TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›SNYNF
SNYNF logo

SNYNF

Sanofi

Next earnings Jul 30, 2026 · consensus $1.89 EPS, $11.4B rev

Sell
$84.71
▲ +0.41%
$84.71▼ -5.37%
over 1Y
L $80.81H $98.92
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.4%
1W-0.6%
1M+0.9%
3M-5.6%
YTD-8.5%
1Y-5.4%
OverviewValuationQualityFilings
Rating
Sell
Quality
—
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 29 analysts
Buy

Mixed signals in the latest filings.

Sanofi shows limited reported revenue.

On these fundamentals, SNYNF screens as SELL on the SEC figures.

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 20, 2026, 3:11 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Is SNYNF a buy? The one-page verdict, explained →

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$101B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-3.5%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
11-KPeriod ending 2025-12-312026-06-30open ↗11-KPeriod ending 2025-12-312026-06-30open ↗NT 11-KPeriod ending 2025-12-312026-06-30open ↗NT 11-KPeriod ending 2025-12-312026-06-30open ↗6-KPeriod ending 2026-06-242026-06-24open ↗6-KPeriod ending 2026-06-222026-06-22open ↗6-KPeriod ending 2026-06-122026-06-12open ↗6-KPeriod ending 2026-06-082026-06-08open ↗SDFiling2026-05-28open ↗6-KPeriod ending 2026-05-272026-05-27open ↗13F-HRPeriod ending 2026-03-312026-05-07open ↗SCHEDULE 13GFiling2026-05-06open ↗

Quality score

—
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
Momentum—
0.0052-week0.00
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is Sanofi (SNYNF) a buy?
SNYNF currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Sources: SEC EDGAR (CIK 0001121404, latest 11-K filed 2026-06-30) · EODHD · as of 6/20/2026, 7:11:18 AM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2021-09-14
Sanofi
10% owner
Buy51.5M @ $38.00$1.96B
2021-09-14
Sanofi
10% owner
Buy20.5M @ $38.00$780M
2021-08-02
Sanofi
10% owner
Acquired (C)3.09M
2021-08-02
Sanofi
10% owner
Buy66.7K @ $15.00$1.00M
2020-07-28
Sanofi
10% owner
Acquired (C)439K
2020-07-28
Sanofi
10% owner
Buy81.3K @ $16.00$1.30M
2020-06-09
Sanofi
10% owner
Sell120K @ $597.48$71.8M
2020-05-29
Sanofi
10% owner
Sell20.4M @ $509.85$10.4B
2020-05-29
Sanofi
10% owner
Sell2.40M @ $509.85$1.22B
2020-03-09
Sanofi
10% owner
Sell129K @ $489.65$63.1M
2019-09-10
Sanofi
10% owner
Sell173K @ $281.15$48.6M
2019-07-22
Sanofi
10% owner
Acquired (C)464K

Dividends

Annual
Yield (TTM)
5.8%
Annual / share
$4.92
Last ex-date
2026-05-06
Last amount
$4.92
ex 2026-05-06paid 2026-05-07$4.92
ex 2025-05-13paid 2025-05-14$4.09
ex 2025-05-12$4.41
ex 2024-05-13paid 2024-05-15$4.05
ex 2023-05-30paid 2023-06-01$3.81
ex 2022-05-06paid 2022-05-10$3.49

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Recent news

market news →
ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFIBullish
finance.yahoo.com· 2026-07-03
Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued GrowthBullish
finance.yahoo.com· 2026-07-03
[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Bullish
finance.yahoo.com· 2026-07-03
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday TradingBearish
finance.yahoo.com· 2026-07-01
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease StudyBullish
finance.yahoo.com· 2026-07-01
The European Investment Bank Grants Orano a Loan of €125 Million to Finance Orano Med’s Innovations and Industrial InfrastructureBullish
finance.yahoo.com· 2026-07-01

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score— vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 4d
Bearish
-0.53
vs typical · 7 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.